Cytokine signatures in chronic fatigue syndrome patients (2017) Roerink

Discussion in 'ME/CFS research' started by Cheesus, Dec 30, 2017.

  1. Cheesus

    Cheesus Established Member (Voting Rights)

    Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment

    Cytokine disturbances have been suggested to be associated with the Chronic Fatigue Syndrome/Myalgic encephalomyelitis (CFS/ME) for decades.

    Fifty female CFS patients were included in a study on the effect of the interleukin-1-receptor antagonist anakinra or placebo during 4 weeks. EDTA plasma was collected from patients before and directly after treatment. At baseline, plasma samples were collected at the same time from 48 healthy, age-matched female neighborhood controls. A panel of 92 inflammatory markers was determined in parallel in 1 μL samples using a ‘proximity extension assay’ (PEA) based immunoassay. Since Transforming growth factor beta (TGF-β) and interleukin-1 receptor antagonist (IL-1Ra) were not included in this platform, these cytokines were measured with ELISA.

    In CFS/ME patients, the ‘normalized protein expression’ value of IL-12p40 and CSF-1 was significantly higher (p value 0.0042 and 0.049, respectively). Furthermore, using LASSO regression, a combination of 47 markers yielded a prediction model with a corrected AUC of 0.73. After correction for multiple testing, anakinra had no effect on circulating cytokines. TGF-β did not differ between patients and controls.

    In conclusion, this study demonstrated increased IL-12p40 and CSF-1 concentrations in CFS/ME patients in addition to a set of predictive biomarkers. There was no effect of anakinra on circulating cytokines other than IL-1Ra.
    Valentijn, Skycloud, TiredSam and 8 others like this.
  2. Cheesus

    Cheesus Established Member (Voting Rights)

    Interesting quote:

    Valentijn, Joh, Forbin and 1 other person like this.
  3. MeSci

    MeSci Senior Member (Voting Rights)

    Cornwall, UK
    The authors are
    Megan E. Roerink, Hans Knoop, Ewald M. Bronkhorst, Henk A. Mouthaan, Luuk J. A. C. Hawinkels, Leo A. B. Joosten and Jos W. M. van der Meer

    Journal of Translational Medicine 2017 15:267

    © The Author(s) 2017

    Received: 20 October 2017

    Accepted: 18 December 2017

    Published: 29 December 2017

    Knoop has an interesting collection of articles, from the absurd to the credible.
    Valentijn, TiredSam, Forbin and 2 others like this.
  4. Webdog

    Webdog Senior Member (Voting Rights)

    Holodeck #2
    IL-12 therapy is also used in non-Hodgkin T-cell Lymphoma, which my sibling died of in her mid 20s.

    Also, IL-12 has been implicated in insulin-dependent Type 1 diabetes mellitus , which one of my parents suffered from.

    Forbin, Inara and MeSci like this.
  5. Forbin

    Forbin Senior Member (Voting Rights)

    In the 2015 Columbia paper, IL-12p40 showed very significant differences between controls and both long- and short-term patients (DN p=0.0012 and UP p= 0.0009. respectively) and between the two patient subsets themselves (p<0.0001).

    The finding was far less significant when short- and long-term patients were combined and measured against controls (DN p=0.0803).
    Last edited: Dec 31, 2017
    pteropus, Inara and Esther12 like this.

Share This Page